Response to: ‘Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian et al’ by Notz et al
| Autor: | Alexis Mathian, Zahir Amoura |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Immunology Disease General Biochemistry Genetics and Molecular Biology law.invention Immune system Rheumatology law Internal medicine medicine Humans Lupus Erythematosus Systemic Immunology and Allergy skin and connective tissue diseases Mechanical ventilation Lupus erythematosus business.industry Hydroxychloroquine medicine.disease Intensive care unit COVID-19 Drug Treatment Antirheumatic Agents Rituximab business medicine.drug |
| Zdroj: | Annals of the Rheumatic Diseases |
| ISSN: | 1468-2060 0003-4967 |
| DOI: | 10.1136/annrheumdis-2020-218795 |
| Popis: | We thank Notz et al for their interest in our study reporting on the course of SARS-CoV-2 disease 2019 (COVID-19) in a case series of patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.1 2 Notz et al report on two patients who had been treated with the anti-CD20 monoclonal antibody rituximab (RTX), prior to SARS-CoV-2 infection, and who presented an exacerbated immune response, a noticeable prolongation of the COVID-19 course and a need for intensive care unit (ICU) admission and mechanical ventilation. Neither one of the patients was able to generate an anti-SARS-CoV-2 spike receptor-binding domain serum antibody response or to eliminate the virus prior to ICU discharge. Because our case series did not include patients receiving B cell depletion therapy, we can only make … |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|